

CITATION REPORT

List of articles citing

A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildra

DOI: 10.3389/fmed.2021.702776
Frontiers in Medicine, 2021, 8, 702776.

Source: <https://exaly.com/paper-pdf/81835736/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
8	Psoriasis between Autoimmunity and Oxidative Stress: Changes Induced by Different Therapeutic Approaches.. <i>Oxidative Medicine and Cellular Longevity</i> , 2022 , 2022, 2249834	6.7	3
7	The relapse of psoriasis: what's the veil of mystery?. <i>JID Innovations</i> , 2022 , 100116		2
6	Emerging Treatment Regimens in Psoriasis: Are There Advantages Over Current Biologic Therapies?. 106-121		0
5	Restoring the Balance between Pro-Inflammatory and Anti-Inflammatory Cytokines in the Treatment of Rheumatoid Arthritis: New Insights from Animal Models.. <i>Biomedicines</i> , 2021 , 10,	4.8	1
4	Clinical evidence on the use of brodalumab for the treatment of psoriasis in Greece: experience from clinical practice of 4 tertiary hospitals.. <i>Dermatologic Therapy</i> , 2022 , e15532	2.2	1
3	Tuscany consensus for the treatment of moderate-severe psoriasis: update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics. <i>Italian Journal of Dermatology and Venereology</i> ,	1.2	
2	NRF2 , a crucial modulator of skin cells protection against vitiligo, psoriasis, and cancer.		0
1	Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge.		0